Business Wire

  1. Sapient Launches DynamiQ As Its Next-Generation Data Insights Engine For Drug Discovery And Development 4/30/2025

    Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics and real-world data (RWD) human biology database, now branded as the DynamiQ Insights Engine, which increases the speed, versatility, and depth of analyses that Sapient can perform to inform drug discovery and precision drug development strategies.

  2. Thermo Fisher Scientific Leverages Integrated Solutions To Accelerate The Development Of Biologic Therapeutics 4/28/2025

    Thermo Fisher Scientific, the world leader in serving science, is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development.

  3. Innorna Announces FDA Rare Pediatric Disease And Orphan Drug Designations Granted To IN013 For Treatment Of Wilson Disease 4/27/2025

    Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD).

  4. CN Bio And Pharmaron Establish Long-Term Strategic Partnership To Develop OOC Technologies On A Global R&D Platform 4/23/2025

    CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry.

  5. Charles River Leverages Advanced Technology To Expedite Oncology Drug Discovery And Development 4/22/2025

    Charles River Laboratories International, Inc., ahead of the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive portfolio of products and services supporting the discovery and development of novel oncology drugs.

  6. TNF Pharmaceuticals And Renova Health Utilize AI To Accelerate Drug Development 4/22/2025

    TNF Pharmaceuticals, Inc. (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.

  7. Argonne Leverages AI And Supercomputing To Revolutionize Cancer Research 4/22/2025

    Discovering new drugs to treat cancer and predicting how tumors will respond to them remain key challenges in the fight against the disease.

  8. Redwire Expands In-Space Drug Development Program, Launches New PIL-BOX Technology And Cancer-Detection Experiment 4/21/2025

    Redwire Corporation, a leader in space infrastructure for the next-generation space economy, announced today that it has launched a new drug development technology and a cancer-detection experiment to the International Space Station (ISS) as the company scales its in-space pharmaceutical drug development program based on the success of its PIL-BOX platform.

  9. Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors 4/21/2025

    Zai Lab Limited today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

  10. Aptar Announces Clinical Validation Study To Accelerate US FDA Approval Of SmartTrack™ In-Vitro-in-Silico Platform For Pressurized Metered-Dose Inhalers 4/16/2025

    AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack platform.